Exetane

Quick links to important sections

Exetane

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Exetane

Property Description
Active ingredient Exemestane
Form Oral film-coated tablet
Pharmacological class Steroidal Aromatase Inhibitor (AI)
Origin Synthetic compound
General Purpose To suppress estrogen production

What Type of Medicine is Exetane? (Definition and Classification)

Exetane is an antineoplastic agent that contains the active compound Exemestane (6-methylideneandrosta-1,4-diene-3,17-dione), which is classified pharmacologically as a Steroidal Aromatase Inhibitor (AI). This designation confirms Exetane as a prescription-only, synthetic steroid derived from androstenedione. This classification as a steroidal type is a key differentiating feature, as its unique action as an irreversible inhibitor sets it apart from non-steroidal analogues like anastrozole or letrozole. Its primary therapeutic purpose is to modify the body’s hormonal environment, thereby providing a foundational method for managing estrogen-dependent diseases, typically utilized in a sequence of hormonal therapy for postmenopausal women.

Composition, Form, and General Therapeutic Purpose

The medicinal product Exetane is administered via the oral route as a single-ingredient product, formulated as a film-coated tablet. The core composition relies on the active ingredient Exemestane, combined with necessary solid pharmaceutical excipients for tablet structure. The general therapeutic benefit stems from its unique function as an irreversible enzyme inactivator. Exemestane's primary action is to permanently block the aromatase enzyme, which is responsible for converting androgens into estrogen in peripheral tissues. This effective and sustained reduction in estrogen is critical for inhibiting the growth of hormone-sensitive cells.

Regulatory References

  1. Exemestane Mechanism (NCI)

What side effects are possible with Exetane?

Possible Side Effects and Safety Information

Exetane (exemestane) carries a safety profile defined by common, usually mild to moderate, adverse reactions and specific, less frequent serious risks identified in regulatory documentation.

Adverse Reaction Scope

Classification Adverse Reactions (Examples) Clinically Significant Considerations
Very Common (ge 10% ) Hot flushes, fatigue, arthralgia (joint pain), headache, insomnia, increased sweating. Risk of long-term bone mineral density (BMD) reduction and subsequent potential for fractures.
Common to Less Common Nausea, dizziness, hypertension, depression, carpal tunnel syndrome, hair loss, and various gastrointestinal or skin reactions. Elevations in liver enzymes (ALT, AST) have been reported, sometimes clinically significant, and may require monitoring.
Serious Adverse Reactions Clinically significant lymphocytopenia (severe reduction in white blood cells), cardiac ischemic events (e.g., myocardial infarction, angina), and rare reports of acute hepatitis/liver injury. Requires immediate medical attention if signs of severe liver issues (e.g., jaundice) or cardiac symptoms occur.

Safety Considerations and Restrictions

Population-Specific Safety: Exetane can cause fetal harm; therefore, it is contraindicated in women who are or may become pregnant. Women of childbearing potential are typically advised to undergo pregnancy testing and use effective non-hormonal contraception during treatment and for a specified period after the final dose.

Monitoring Notes: Regulatory guidelines recommend a formal assessment of bone mineral density (BMD) at the start of treatment, and regular monitoring for BMD loss is necessary, especially for patients with or at risk of osteoporosis. Additionally, assessment and supplementation for Vitamin D deficiency are often recommended prior to beginning treatment.

Contraindications: This medicine should not be used simultaneously with any estrogen-containing medicines, such as hormone replacement therapy, as they interfere with Exetane's primary anti-estrogen action.

Overdose and Emergency Response

Overdose and when to Seek Help

The official regulatory profile for Exemestane (Exetane) indicates that doses significantly higher than the standard, including single doses up to 800 mg, have been administered in clinical studies and were generally well tolerated without a defined characteristic symptom profile. However, in a documented case of accidental ingestion, a transient finding of leucocytosis (high white blood cell count) was observed, which resolved spontaneously without specific intervention.

It is officially stated that no specific antidote to overdosage is known. Consequently, treatment for a known or suspected overdose must be symptomatic and consist of general supportive care. The official prescribing information mandates the frequent monitoring of vital signs and close observation of the patient throughout the management period.

Patients or caregivers must seek immediate medical attention for any suspected overdosage. Urgent medical assistance is required if the affected individual displays life-threatening clinical signs, such as experiencing a seizure, having trouble breathing, collapsing, or being unable to be awakened, as described in government health guidance. The need for emergency care is paramount when such severe outcomes are observed.

Therapeutic Uses of Exetane

What Exetane Treats: Main Uses and Benefits

Exetane is used as a therapeutic approach for addressing conditions related to hormone receptor-positive malignancies across multiple clinical contexts. The medication is commonly used to help manage the risk of recurrence in early breast cancer in postmenopausal women.

It is also relevant in situations where symptoms escalate temporarily, such as in advanced or metastatic breast cancer. The use of this therapy may be used to support management of recurrence risk, and in advanced cases, may assist with managing tumor growth.

Furthermore, Exetane is considered relevant for use in chemoprevention for postmenopausal women identified as being at high risk of developing invasive cancer. The overall benefit supports patients during difficult episodes and may assist with maintaining functional stability.


Quick Fact: Support for Condition Management

This treatment is applied across domains where additional symptomatic support is needed, supports general well-being during symptomatic phases, and is generally used when supportive symptomatic assistance is appropriate.

Eligibility and Restrictions for Use

Who Can and Cannot Use Exetane?

The official eligibility profile for Exetane (Exemestane) is strictly limited by regulatory authorities, primarily based on the patient's hormonal and reproductive status.

Category Eligibility Status
Primary Eligible Population Postmenopausal women. Use is only established in the adult female population who have reached postmenopausal endocrine status.
Absolute Contraindications Premenopausal women, pregnant women, and lactating women. The medicine is also contraindicated in patients with a known hypersensitivity to Exemestane or its excipients.

Key Eligibility Restrictions

Regulatory documents establish that Exetane must not be used concurrently with estrogen-containing agents, as this would negate its intended pharmacological action.

  • Age-Related Rule: Use is not recommended for the pediatric population (children and adolescents) because safety and efficacy have not been established.
  • Organ Function: Patients with moderate or severe hepatic or renal impairment should use the medicine with caution.
  • Contraception Requirement: Females of reproductive potential are required to use effective non-hormonal contraception during treatment and for one month after the last dose.
  • Assessment Requirement: For women with or at risk of osteoporosis, a formal bone mineral density (BMD) assessment is required before starting treatment.

What should I know about interactions with other medicines?

Interaction scope

Property Description
Medicinal product categories with documented interactions: Estrogen-containing agents, Strong CYP3A4 Inducers
Specific interacting medicines (if explicitly listed): Rifampicin, Phenytoin, Carbamazepine, Phenobarbital
Mechanistic basis of interactions (only if stated in label): Pharmacokinetic interaction (CYP3A4 induction decreases exposure); Pharmacodynamic interaction (antagonism with estrogens)
Timing-based interaction rules (if applicable): Co-administration with strong CYP3A4 inducers requires taking the adjusted dose after a meal.
Population-specific interaction notes (if applicable): Severe hepatic or renal impairment results in an approximately two- to three-fold higher exposure (AUC) due to reduced clearance.
Interaction-related restrictions: Estrogen-containing agents must not be co-administered as they interfere with the drug's intended action.

Interaction classifications (high-level)

Property Description
Interaction severity classification: Contraindicated (for estrogen agents); Significant exposure reduction (for strong CYP3A4 inducers)
Regulatory basis: FDA Labeling, EMA Summary of Product Characteristics (SmPC)
Interaction-context constraints (as defined in official documents): For co-administration with a strong CYP3A4 inducer, a dose increase is officially recommended.

Resulting interaction structure

Official interaction statements:

  • Estrogen-containing agents are contraindicated because they cause pharmacodynamic interference, negating the purpose of the drug.
  • Co-administration with strong CYP3A4 inducers significantly reduces Exetane plasma exposure; this also applies to the herbal product St. John's wort.
  • Individuals with severe hepatic or renal impairment experience reduced clearance, resulting in a documented increase in drug exposure.

Connection to the overall interaction profile (2–4 sentences):

Official regulatory documents define the interaction profile by classifying interactions into pharmacodynamic antagonism with estrogens and pharmacokinetic alterations via the CYP3A4 metabolic pathway. This structure identifies substances that severely diminish drug exposure and details specific population factors that increase it, establishing label-based constraints for co-administration.

Mechanism of Action

How Exetane Works

The action of Exetane is defined by its highly specific and permanent engagement with the body's hormonal production machinery, resulting in prolonged reduction of circulating estrogen levels. The mechanism operates through two core domains: permanent enzyme inactivation and targeted hormonal blockade.


Permanent Enzyme Inactivation: The Mechanism-Based Inactivator

Exetane acts as a mechanism-based inactivator by targeting the Aromatase Enzyme (CYP19A1). The drug functions as a substrate that the enzyme attempts to metabolize, but this process converts Exemestane into a highly reactive intermediate that forms a permanent, covalent bond at the active site. This irreversible molecular lock-down takes the enzyme out of commission, ensuring the functional block on the pathway is prolonged, as recovery requires new enzyme synthesis.


Targeted Systemic Estrogen Deprivation

The permanent inactivation of Aromatase directly halts the final step in the Estrogen Biosynthesis Pathway, preventing the conversion of androgens into active estrogens (Estradiol and Estrone) primarily in peripheral tissues (e.g., fat and muscle). This mechanism is highly relevant in states where these tissues are the dominant source of the hormone, leading to a marked and sustained systemic hypoestrogenism. This resulting physiological state of estrogen depletion eliminates a hormonal signal that drives proliferation in estrogen-dependent cells.

Dosage and Administration Information

How to Use Exetane

Exetane (Exemestane) is an oral medication with a standardized administration protocol focusing solely on the correct route, dose, frequency, and duration of use. The approved medicinal form is a 25 mg film-coated tablet intended for administration via the oral route.


Standard Dosing and Administration

The standard adult dosing regimen is 25 mg taken once daily. A critical instruction for proper administration is that the tablet must be consumed after a meal. This specific timing is required to ensure consistent absorption. If a dose is missed, standard clinical protocols advise taking the next dose at the usual scheduled time; patients should not take a double dose to compensate.

Duration and Contextual Adjustments

The course duration is tied to the clinical context. For patients receiving adjuvant therapy, daily administration is continued to complete a total period of five years of hormonal treatment. In the advanced disease setting, the medication is continued until there is evidence of tumour progression.

Specific dosing modifications are mandatory in certain situations. The daily dose must be increased to 50 mg when Exetane is co-administered with a strong CYP 3A4 inducer. Clinical documentation also clarifies that no dose adjustment is required for patients with either renal or hepatic impairment.

Recent Clinical Evidence

Evidence Overview: Understanding the Research for Exetane


Research for Early Breast Cancer (Sequential Therapy)

Exetane was studied for its use in postmenopausal women who had already completed 2 to 3 years of treatment with Tamoxifen for hormone receptor-positive early breast cancer. The research explored the outcomes of switching to Exetane after 2 to 3 years of Tamoxifen, compared to the strategy of continuing with Tamoxifen alone, as part of a total 5-year hormonal treatment plan.

These large-scale Randomized Controlled Trials (RCTs) involved thousands of patients. Researchers examined the time until a cancer event returned (known as Disease-Free Survival) and also the time to death (Overall Survival). Findings describe patterns observed in the studies where the switch to Exetane was observed in the rates of cancer returning.

Research for Advanced or Metastatic Breast Cancer

Exetane was evaluated in research for women with advanced or metastatic hormone receptor-positive breast cancer that had progressed after they had already received another type of hormonal therapy. These Phase II/III trials researched how the medication was observed to perform against older hormonal agents or when used in combination with other targeted treatments.

Data show patterns related to progression-free survival in the population whose disease had already advanced, and studies contribute to the broader evidence landscape regarding this condition when initial treatment has stopped working.


Long-Term Studies and Follow-Up Data

For the treatment of early breast cancer, researchers explored the outcomes far beyond the initial 5-year treatment window. Long-term effects are not fully established, but data show patterns related to survival and recurrence up to 10 to 12 years after the women entered the study.

What is Still Uncertain About Exetane

While extensive research was conducted for Exetane, several areas remain uncertain. For the advanced cancer setting, comparative evidence is limited against some of the current treatment options. Overall, long-term effects are not fully established beyond the observation windows reported by the research, and findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Exetane (FAQ)


Q: How is Exetane different from other medicines used for the same condition?

A: Exetane is classified as a Steroidal Aromatase Inhibitor (AI). According to official labeling, it works by permanently and irreversibly inactivating the aromatase enzyme, which is the mechanism that produces estrogen. This irreversible binding is a key feature that is described as distinguishing it from non-steroidal AIs, which bind to the enzyme reversibly.

Q: Can Exetane cause weight gain?

A: Yes, regulatory documents list weight gain as one of the reported adverse reactions observed in patients taking Exetane during clinical studies. It is described as a common effect associated with the medication.

Q: Is it normal to feel tired or fatigued when starting Exetane?

A: Yes, fatigue and general feelings of tiredness are documented in the official product information as a very common side effect. This means it was observed in 10% or more of patients during clinical trials. Information about side effects is provided to assist in discussions with a health care provider.

Q: What happens if I forget to take a dose of Exetane?

A: If a dose is missed, regulatory guidance advises simply taking the next dose at the usual scheduled time. Official instructions caution patients against taking a double dose to compensate for the missed one.

Q: Can Exetane affect my mood or cause emotional changes?

A: Yes, official adverse reaction reports include mood changes such as depression and anxiety among the reported side effects. Difficulty sleeping (insomnia) is also a common side effect which is noted to sometimes impact mood.

Q: Can I take Exetane if I have a history of heart problems?

A: Regulatory documents list cardiac ischemic events (such as heart attack or angina) as serious adverse reactions that have been reported more frequently with Exetane in some studies. Official guidance notes that patients with a history of heart problems may be subject to monitoring by their health care team.

Q: Is it common to need a dose adjustment while on Exetane?

A: Dose adjustment is not a common or routine occurrence for most patients using Exetane. However, a dose increase is specifically mandated in official documents when the medication is co-administered with certain strong enzyme-inducing medicines, such as Rifampicin.

Q: Can Exetane cause dizziness?

A: Yes, according to the official product information, dizziness is documented as a common side effect of Exetane. The potential for dizziness is a consideration related to activities such as driving or operating machinery.

Q: Does Exetane affect my sleep?

A: Yes, problems with sleep are reported in the official adverse reaction data. Specifically, insomnia (difficulty falling asleep or staying asleep) is documented as a very common side effect of Exetane.

Q: How long does it typically take to feel the full effects of Exetane?

A: The hormonal effect of Exetane is seen relatively quickly. Pharmacological studies indicate that the maximal suppression of circulating estrogen levels typically occurs approximately two to three days after the first dose. This hormonal blocking effect is then sustained throughout treatment.

Q: Are there any long-term effects of taking Exetane?

A: One long-term effect documented in official safety information is a reduction in bone mineral density (BMD), which may increase the risk of fractures. Long-term follow-up data extending up to 10 to 12 years from initial studies are available, but the full spectrum of long-term effects is acknowledged to be not fully established.

Q: Is Exetane a chemotherapy drug?

A: No, Exetane is not considered a traditional chemotherapy drug. It is officially classified as an antineoplastic agent (a broad term for cancer treatments) and more specifically as a Steroidal Aromatase Inhibitor. It works by modifying the body's hormones rather than directly attacking cells.

Q: Are there certain foods or supplements I should avoid with Exetane?

A: Official information advises strictly avoiding any products containing estrogen, including estrogen-containing herbal supplements, as they interfere with the drug's action. The herbal product St. John's wort is also documented as having an interaction. Additionally, some authoritative patient materials note that grapefruit juice and Seville oranges may be a consideration.

Q: Will Exetane cause my hair to thin or fall out?

A: Yes, hair loss (alopecia) and hair thinning are listed in the authoritative documentation among the reported side effects of Exetane.

Q: Does Exetane require special monitoring or blood tests?

A: Yes, regulatory documents recommend specific monitoring. This includes a formal assessment and routine monitoring of bone mineral density (BMD), and the assessment and supplementation for Vitamin D levels. Blood tests may also be needed to check for unwanted effects, such as changes in liver enzymes.

Q: Can men use Exetane for any approved condition?

A: No. The official regulatory indications for Exetane are specifically limited to the treatment of breast cancer in postmenopausal women. Use in men for any condition is not established in the official labeling.

Q: Can Exetane affect my cholesterol levels?

A: Yes, the official labeling notes that hypercholesterolemia (high cholesterol levels) and increases in other lipid levels have been reported with Exetane use. Cholesterol levels may be monitored by the health care team.

Q: How do doctors monitor the effectiveness of Exetane treatment?

A: While the general drug label does not specify all clinical tests, for advanced disease, official guidance states that treatment is continued until tumor progression is evident. This suggests that monitoring for effectiveness involves periodic assessments of the disease status through methods like imaging or tumor markers.

Q: Is it okay to take multivitamins while on Exetane?

A: General multivitamins are not specifically listed as an interaction. However, authoritative sources state that all supplements, vitamins, and natural health products should be reviewed by a health care team, especially to ensure they do not contain any estrogenic ingredients.

Q: Will I experience withdrawal symptoms if I stop taking Exetane?

A: Regulatory documents do not specifically mention 'withdrawal symptoms.' However, authoritative resources note that some side effects may persist even after the medication is stopped, and stopping treatment earlier than advised may increase the risk of cancer recurrence.

Q: What does 'adjunctive treatment' mean in relation to Exetane?

A: In the context of cancer care, 'adjuvant treatment' or 'adjunctive treatment' refers to using the medicine as a follow-up therapy after the initial treatments, like surgery or radiation. The goal is to eliminate any remaining disease and prevent the cancer from returning.

Q: What if I experience unusual swelling while taking Exetane?

A: Swelling of the hands, ankles, feet, or lower legs (peripheral edema) is listed as a reported side effect of Exetane. The official product information states that any unusual, severe, or worrying symptoms, including significant or sudden swelling, should be promptly reported to a health care provider.

Q: Can I take Exetane with blood pressure medication?

A: Official drug labels do not list blood pressure medications as being strictly contraindicated with Exetane. However, hypertension (high blood pressure) is listed as a common side effect of Exetane itself. Review of the concurrent use of Exetane with any other heart or blood pressure medications by a health care team is described as necessary.

Q: What is the difference between Exetane and a selective estrogen receptor modulator (SERM)?

A: Exetane, an Aromatase Inhibitor (AI), works by drastically reducing the amount of estrogen the body is able to make in peripheral tissues. A SERM (such as Tamoxifen) works differently by blocking the action of estrogen at the receptor sites on cells, but it does not stop the body from producing estrogen.

Q: Does Exetane have an effect on sexual drive?

A: Due to the significant reduction in circulating estrogen that is caused by this class of medication, authoritative resources note that a decreased sexual interest (libido) and symptoms like vaginal dryness are frequently reported consequences of taking Aromatase Inhibitors.

Q: Does Exetane interact with alcohol?

A: Authoritative sources note that alcohol may need to be avoided or limited while taking Aromatase Inhibitors like Exetane. Excessive consumption may potentially decrease the efficacy of the medication or worsen certain side effects.

Q: How long does Exetane stay in the body after stopping treatment?

A: Exemestane has a relatively short terminal half-life of approximately 24 hours. However, its primary effect—the reduction of estrogen—is prolonged because the drug permanently inactivates the aromatase enzyme, meaning the body must synthesize new enzyme to recover hormonal function.

Q: What official documents say about Exetane and driving?

A: Official documents state that Exetane has a moderate influence on the ability to drive and use machines. This is because side effects like drowsiness, asthenia (weakness), and dizziness have been reported. Caution is advised for activities such as driving, and operating a vehicle is not recommended if these effects are experienced.

Q: Is Exetane safe to use for people with kidney disease?

A: Regulatory documents state that no dose adjustment is required for patients with renal impairment. However, use in patients with moderate or severe renal impairment is advised to be with caution, as the safety of chronic dosing has not been fully studied in this specific group.

Q: How often should I report side effects from Exetane to my care team?

A: Official guidance notes that any unusual, severe, or worrying symptoms, or any signs of a serious side effect (such as jaundice or chest pain), should be promptly reported to a health care provider. Routine or less severe side effects are typically discussed at scheduled appointments.

Q: Is Exetane a generic medicine?

A: Yes, the active ingredient in Exetane, Exemestane, is available as a generic medicine. The original brand name for Exemestane was Aromasin.

How should Exetane be stored and disposed of?

How to Store and Dispose of Exemestane (Exetane)

The official labeling for Exemestane tablets dictates strict storage conditions to maintain the medicine's quality and ensure safety.

Storage Requirements

  • Temperature: The product must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Brief temperature excursions are permitted between 15 C and 30 C.
  • Container: The medicine must be kept in the original container (blister and carton) and must not be used beyond the expiry date printed on the packaging.
  • Child Safety: A mandatory requirement is to keep the medicine out of the sight and reach of children.

Official Disposal Instructions

Official regulatory guidance outlines the proper disposal of unused or expired tablets. The primary method is to return the unused medicine to a formal drug take-back program at a local collection site. If a take-back program is unavailable, official guidelines instruct mixing the tablets with an unpalatable substance and placing the mixture in a sealed container before discarding it in the household trash. Disposal should not involve throwing the medicine into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Exetane found in:

A-Z Index: